A Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 in Preventing SARS-CoV-2 infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff

In the USA, at least 153,000 residents and employees of nursing homes have contracted COVID-19, accounting for 35% of the country's deaths. With over 1.3 million residents in nursing home care, there is an urgent need for therapeutic strategies to prevent COVID-19 in these populations. This study aims to evaluate the impact of LY3819253 in preventing SARS-CoV-2 infection and COVID-19 in facility staff and residents in skilled nursing and assisted living facilities.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  SARS-CoV-2 riskCOVID-19 risk
• Age: Between 18 Years - 99 Years
• Gender: All